key: cord-0706560-x9xrjx3x
authors: Aksoyalp, Zinnet Şevval; Nemutlu-Samur, Dilara
title: Sex-related susceptibility in coronavirus disease 2019 (COVID-19): Proposed mechanisms
date: 2021-10-02
journal: Eur J Pharmacol
DOI: 10.1016/j.ejphar.2021.174548
sha: ce1528454f17b1a7c39256a44611e7f93b9b8d46
doc_id: 706560
cord_uid: x9xrjx3x

The importance of sex differences is increasingly acknowledged in the incidence and treatment of disease. Accumulating clinical evidence demonstrates that sex differences are noticeable in COVID-19, and the prevalence, severity, and mortality rate of COVID-19 are higher among males than females. Sex-related genetic and hormonal factors and immunological responses may underlie the sex bias in COVID-19 patients. Angiotensin-converting enzyme 2 (ACE2) and transmembrane protease/serine subfamily member 2 (TMPRSS2) are essential proteins involved in the cell entry of SARS-CoV-2. Since ACE2 is encoded on the X-chromosome, a double copy of ACE2 in females may compensate for virus-mediated downregulation of ACE2, and thus ACE2-mediated cellular protection is greater in females. The X chromosome also contains the largest immune-related genes leading females to develop more robust immune responses than males. Toll-like receptor-7 (TLR-7), one of the key players in innate immunity, is linked to sex differences in autoimmunity and vaccine efficacy, and its expression is greater in females. Sex steroids also affect immune cell function. Estrogen contributes to higher CD4(+) and CD8(+) T cell activation levels, and females have more B cells than males. Sex differences not only affect the severity and progression of the disease, but also alter the efficacy of pharmacological treatment and adverse events related to the drugs/vaccines used against COVID-19. Administration of different drugs/vaccines in different doses or intervals may be useful to eliminate sex differences in efficacy and side/adverse effects. It should be noted that studies should include sex-specific analyses to develop further sex-specific treatments for COVID-19.

1 2021). Therefore, pulmonary TMPRSS2 regulation seems not to count in sex differences in 2 COVID-19 clinical outcomes (Baratchian et al., 2021) . Toll-like receptors (TLRs) that recognize bacterial or viral DNA/RNA are the key innate 13 immune pattern recognition receptors (Alwani et al., 2021) . They are expressed on both the 14 innate immunity cells (DCs, macrophages, natural killer cells) and adaptive immunity cells (T 15 cells and B cells) (Khanmohammadi and Rezaei, 2021) . There are ten different types of TLRs 16 in the human genome as TLR1-10 (Khanmohammadi and Rezaei, 2021) . The expression of 17 TLRs is sex-specific (Pradhan and Olsson, 2020). TLR-3, TLR-7, and TLR-9 recognizing viral 18 nucleic acids are female-biased, while TLR-2 and TLR-4 recognizing bacterial nucleic acids 19 are male-biased (Pradhan and Olsson, 2020). Among them, TLR-7 is linked to sex differences 20 in autoimmunity and vaccine efficacy since it escapes X chromosome inactivation, resulting in 21 greater expression in female immune cells (Scully et al., 2020) . Upon recognizing viral infection, TLR7 triggers the production of type I interferons (IFNs) with antiviral functions to 23 control viral replication and activate an adaptive immune response to clear the infection 1 explains the enhanced susceptibility to viral infections in males (Di Resta et al., 2021) .

Once the SARS-CoV-2 enters the cell and is recognized by alveolar macrophages, the 3 production of proinflammatory cytokines and chemokines is triggered (Wehbe et al., 2021). 4 Studies showed that greater upregulation of proinflammatory cytokines, including IL-7, IL- 16, 5 and IL-18, in males with COVID-19 infection compared with females (Haitao et al., 2020; 6 Takahashi et al., 2020) . At the early stage of viral invasion, a more robust inflammatory 7 response of females helps a rapid clearance of the virus (Xu et al., 2020) . If the virus is not 8 cleared timely, it causes overreaction in immune response, and excessive cytokine production 9 leads to a cytokine storm with a widespread inflammation and multi-organ damage (Wehbe et -19 patients (Beigel et al., 2020) . The recovery rate ratio for female patients using 2 remdesivir was slightly higher than male ones (Beigel et al., 2020) ; however, the authors did 3 not mention if this difference is statistically significant or not.

The off-label use of anti-inflammatory drugs to alleviate excessive inflammation is also 5 noticeable. The Colchicine Coronavirus SARS-CoV-2 Trial (COLCORONA) showed that 6 colchicine led to a lower rate of the composite of death or hospital admission than placebo 7 (Tardif et al., 2021). However, while the primary efficacy composite endpoint was reduced by 8 colchicine in the total cohort and males, a subgroup analysis pointed to a lower efficacy in 9 females (Tardif et al., 2021). Furthermore, preclinical reports mentioned a higher acute oral 10 toxicity of colchicine in female rats as than males, and that female rats were two times more 11 susceptible to the lethal effects of colchicine than male rats (Wiesenfeld et al., 2007) . According 12 to previous studies, immunomodulators (i.e., corticosteroids, iv immunoglobulin, tocilizumab, COVID-19 (Xu et al., 2020) . Only in a study evaluating the 16 pharmacokinetics of methylprednisolone, it was found that females were more sensitive to it; 17 however, the efficacy of methylprednisolone in females was similar to the males since females 18 have rapid clearance and short elimination half-life (Lew et al., 1993) . Because convalescent 19 plasma contains potentially therapeutic antibodies to SARS-CoV-2, it has been widely used for 20 COVID-19 (Joyner et al., 2021) . For the proof of concept, Fink et al., showed that the transfer 21 of antibodies from vaccinated females into naïve mice (males or females) provided better 22 protection against influenza (Fink et al., 2018) . In their prospective study, Duan et al. showed 23 that convalescent plasma is safe, and it improves symptoms and laboratory parameters and 24 reduces viral load (Duan et al., 2020) . In another retrospective study, Joyner et al., showed that convalescent plasma with higher anti-SARS-CoV-2 IgG antibody levels were associated with 1 a lower risk of death (Joyner et al., 2021) . Although both studies include more male patients 2 than female patients, the authors did not perform sex-specific analyses. Evidence shows that the pharmacokinetics process of antiviral drugs varies between males and 11 females and that adverse drug reactions to antiviral drugs are more frequent in females than 12 males (Shiau et al., 2014). It was found that when lopinavir or ritonavir is administered in the 13 same dose, plasma concentrations of ritonavir were higher in females (Smith et al., 2014) . 14 However, atazanavir plus ritonavir combination was related to a higher risk of virologic failure 15 in females than in males, probably because of low adherence and tolerability of atazanavir plus 16 ritonavir in females (Smith et al., 2014) . Atazanavir clearance was also slower in females, and 17 thus, its levels were higher in females than males (Smith et al., 2014) . It may be because that 18 the glomerular filtration rate is higher in males than in females (Schwartz, 2003) . Sex 19 differences in pharmacokinetics may result from the discrepancy in body surface area, weight, 20 and water/fat distribution between males and females. For example, gastric motility is faster in Furst, 1996) . In a study that evaluated suspected adverse drug reactions with favipiravir, severe 23 and fatal adverse reactions were more reported in males (68%) than females (32%), and most 24 adverse reactions are hepatic enzyme increase (23.66%) and nausea and vomiting (13.98%) 1 (Helms et al., 2020) . Current data reveals that thromboembolism and worse outcomes are more 2 possible in male patients with severe COVID-19 than in females because of hypercoagulability 3 with fibrin formation and polymerization (Spiezia et al., 2020) . One of the possible explanations 4 of this finding includes that estrogen can reduce plasma levels of fibrinogen and increase 5 antithrombin III and decrease plasminogen activator inhibitor type 1 (PAI-1) (Li et al., 2020) . 6 On the other hand, testosterone enhances endothelial NO production, thereby potently (Table 1) . Females were higher likely to report adverse effects 17 than males after the first dose of BNT162b2 (16.2% vs. 9 .3%) and ChAdOx1 nCoV-19 (39.3% Table 1 ). The benefits of the mRNA vaccine were greater because myocarditis and pericarditis 23 cases were rare and treatable. After Janssen COVID-19 vaccination, an overage number of 24 Guillain-Barré syndrome cases were more reported in males aged 50-64 years (15.6 cases per 1 aged 30-49 years (8.8 cases per million) (Rosenblum et al., 2021) . In the CoronaVac (Sinovac 2 Life Sciences) phase 3 study, the incidence of adverse events in the vaccine group was low 3 (18.9%) without deaths or grade 4 adverse events (Tanriover et al., 2021) . The most frequent 4 systemic and local adverse event was fatigue (8.2%) and injection-site pain (2.4%) (Tanriover 5 et al., 2021). More males (57.4%) were involved in this study; however, no clear causal effect 6 or sex-related difference of the events was confirmed. Other than the vascular adverse effects, 7 injection site reactions and hypersensitivity are more commonly reported after vaccination in 8 females (Cook, 2009; Griffioen and Halsey, 2014) . Stronger immune responses of females may 9 increase the efficacy of vaccines but also leads to more adverse reactions (fever, pain, and 10 inflammation) (Fischinger et al., 2019; Klein et al., 2015) . Administration of vaccines in 11 different doses or intervals or administering different vaccine candidates to males and females 12 may prevent negative consequences related to sex differences (Fathi et al., 2020) . Xu, K., Chen, Y., Yuan, J., Yi, P., Ding, C., Wu, W., Li, Y., Ni, Q., Zou, R., Li, X., Xu, M., 8 Zhang, Y., Zhao, H., Zhang, X., Yu, L., Su, J., Lang, G., Liu, J., Wu, X., Guo, Y., Tao, J., Shi, 

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a 18 systematic review and meta-analysis

The emergence of a novel coronavirus

CoV-2) disease and their neuroinvasive propensity may affect in COVID-19 patients

Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety 25

Sex-Related Overactivation of NLRP3 Inflammasome 27 Increases Lethality of the Male COVID-19 Patients